Medtronic plc. (MDT) exhibits 65.0% gross margins and 7.8% return on invested capital within Health Care (Biotechnology: Electromedical & Electrotherapeutic Apparatus), balanced against a 17.4x enterprise multiple and 4.8% implied options volatility.
Sustained 65.0% gross profitability converts into 17.8% operating margin and 7.8% ROIC, outpacing sector cost of capital.
ROIC: 7.8% // GM: 65.0%YoY revenue trajectory of +8.4% paired with 4.37% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +8.4% // FCF YLD: 4.37%Altman Z-Score of 3.08 and Piotroski F-Score of 9/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.08 // F-SCORE: 9/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: 17.4xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $96.54 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Electromedical & Electrotherapeutic Apparatus require continuous execution to defend 0.0% net margins.
NET MARGIN: 0.0% // D/E: 0.36x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for MDT & activate live FRED threshold breach alerts.